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O B J E C T I V E S This study examined a large cohort to assess whether progression of coronary artery
calcium (CAC) was associated with all-cause mortality, and which among 3 different methods to assess
CAC progression provided the best estimate of risk.
B A C KG ROUND Serial assessment of CAC scores has been proposed as a method to follow
progression of coronary artery disease, and it has been suggested that excessive CAC progression may
be a useful noninvasive predictor of the patient’s risk of future events. However, the optimal method to
measure calcium progression has not been well established.
METHOD S The study sample consisted of 4,609 consecutive asymptomatic individuals referred by
primary physicians for CAC measurement with electron beam tomography, who underwent repeat
screening. Three general statistical approaches were taken: 1) the absolute difference between follow-up
and baseline CAC score; 2) percent annualized differences between follow-up and baseline CAC score;
and 3) difference between square root of baseline and square root of follow-up CAC score 2.5 (the
“SQRT method”).
R E S U L T S The average interscan time was 3.1 years, and there were 288 deaths. Progression of CAC
was signiﬁcantly associated with mortality regardless of the method used to assess progression (p 
0.0001). After adjusting for baseline score, age, sex, and time between scans, the best CAC progression
model to predict mortality was the SQRT method (hazard ratio [HR]: 3.34; 95% conﬁdence interval [CI]:
2.65 to 4.21; p 0.0001), followed by a15% yearly increase (HR: 2.98; 95% CI: 2.20 to 4.95; p 0.0001).
Progression was very limited and did not predict mortality in patients with baseline CAC  0.
CONC L U S I O N S The CAC progression added incremental value in predicting all-cause mortality
over baseline score, time between scans, demographics, and cardiovascular risk factors. Serial assess-
ment may have clinical value in assessing plaque progression and future cardiovascular risk. (J Am Coll
Cardiol Img 2010;3:1229–36) © 2010 by the American College of Cardiology Foundation
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1230s a sensitive marker of atherosclerosis, coro-
nary artery calcium (CAC) has been pro-
posed as a method to follow progression of
coronary artery disease. However, ran-
omized clinical trials that used sequential com-
uted tomography (CT) scanning failed to uni-
ormly demonstrate that CAC can to be used to
onitor response to medical therapy for atheroscle-
osis. In spite of this, 1 trial (1) and a few observa-
ions (2–4) have shown that the progression of
AC is a marker of increased risk of future cardio-
ascular events. Similarly, early trials using quanti-
ative invasive coronary angiography conclusively
emonstrated that atherosclerosis progression is a
arbinger of adverse outcomes. Hence, excessive
AC progression may be a useful noninvasive
redictor of the patient’s risk of future events.
onetheless, the evidence so far accumulated is
mall (1–4), and little is known of the development
f CAC and its significance in subjects without
AC at baseline. Therefore, in this study, we
verified the all-cause mortality of patients
who underwent at least 2 CT scans for
quantification of CAC. We further as-
sessed which of several methods to esti-
mate CAC progression was more accurate
to predict mortality, and whether absence
of CAC at baseline and its development
are independently associated with all-
cause mortality.
M E T H O D S
he study sample consisted of 4,609 consecutive
symptomatic individuals referred by primary care
hysicians for CAC measurement with electron
eam tomography (EBT), who underwent sequen-
ial scans at least 10 months apart. Patients under-
ent repeat scans, as per their primary physician, to
ssess change in atherosclerosis risk over time. This
tudy received the approval of the institutional
eview board.
Patients with a history of coronary artery disease
i.e., admission to the hospital for chest pain, acute
oronary syndrome, or myocardial infarction [MI],
s well as prior coronary revascularization) were
xcluded. Also, patients suffering an interim event
etween scans were excluded. Subjects were given a
isk-factor questionnaire to assess ethnicity and
ardiovascular risk factors at baseline and follow-up.
he presence and number of risk factors for each
ubject was calculated based on the National Cho-
mesterol Education Program guidelines (5). Risk yactors included: age (men age 45 years of age,
omen 55 years of age), current cigarette smok-
ng, diabetes mellitus, history of premature coronary
rtery disease in first-degree relatives (men 55
ears of age, women 65 years of age), hyperten-
ion, and hypercholesterolemia. Current cigarette
moking was defined as any cigarette smoking in
he past month. Hypertension was defined by cur-
ent use of antihypertensive medications or known
nd untreated hypertension. Hypercholesterolemia
as defined as use of cholesterol-lowering medica-
ions or, in the absence of cholesterol-lowering
edication use, as having a total serum cholesterol
200 mg/dl. Statin use was recorded at the time of
canning at both baseline and follow-up.
maging methods. All study subjects underwent 2
BT scans using an Imatron C-300 computed
omography scanner (GE Imatron, South San
rancisco, California). Thirty to forty contiguous
omographic slices were obtained at 3-mm intervals
eginning 1 cm below the carina and progressing
audally to include the entire coronary tree. Expo-
ure time was 100 ms per tomographic slice, and
otal radiation dose was 0.6 mSv per scan.
alcium scoring. All scans were analyzed with a
ommercially available software package (Neo Im-
gery Technologies, City of Industry, California).
n attenuation threshold of 130 Hounsfield units
HU) and a minimum of 3 contiguous pixels were
tilized for identification of a calcific lesion. Each
ocus exceeding the minimum criteria was scored
sing the algorithm developed by Agatston et al.
6), calculated by multiplying the lesion area by a
ensity factor derived from the maximal HU within
his area. The density factor was assigned in the
ollowing manner: 1 for lesions with peak attenua-
ion of 130 to 199 HU, 2 for lesions with peak
ttenuation of 200 to 299 HU, 3 for lesions with
eak attenuation of 300 to 399 HU, and 4 for
esions with peak attenuation 400 HU. The total
AC score was determined by summing individual
esion scores from each of 4 anatomical sites (left
ain, left anterior descending, left circumflex, and
ight coronary artery) (7).
ollow-up data collection. Epidemiologic methods
or follow-up included ascertainment of death by
ndividuals who were blinded to historical and
AC score results (8,9). The occurrence of all-
ause death was verified with the National Death
ndex (10). Individuals who underwent cardiovas-
ular screening were followed for a mean of 5.4 
.4 years after the second scan (range 1.0 to 16.0B B R E V I A T I O N S
N D A C R O N YM S
AC coronary artery calciu
T computed tomography
BT electron beam
omography
U Hounsfield unitears). Follow-up was completed in 100% of pa-
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1231ients; there were 4,609 asymptomatic subjects in
his sample.
tatistical analysis. Categorical variables comparing
AC patient subsets with historical variables were
ompared using a chi-square likelihood ratio test.
or comparing CAC subsets by age and other
ontinuous measures, we employed analysis of vari-
nce techniques. A p value 0.05 was considered
tatistically significant. Time to death from all
auses was estimated using a Cox proportional
azards model. The exposure variable is the pro-
ression of CAC score from baseline to follow-up
can. A priori methods for assessing progression
ere established. Three general approaches were
aken: 1) the difference between follow-up and
aseline absolute CAC score; 2) annualized percent
ifferences between follow-up and baseline CAC
core; and 3) previously established cut points for
rogression of CAC. Specifically:
ifferences:
. the absolute difference between the second and
first measure of coronary calcium [CAC(follow-up) –
CAC(baseline)],
. the square root transformed difference
[CAC(follow-up) – CAC(baseline)] (the “SQRT
method”) (11),
. the natural logarithm plus 25 difference [(ln
CAC(follow-up) 25) – (ln CAC(baseline)  25)].
(the “MESA method”) (12),
. the percent change [(CAC(follow-up) – CAC(baseline))/
CAC(baseline)].
Annualized differences:
he preceding 4 quantitative exposure variables
ivided by the time (in years) between the first and
he second scan.
Pre-defined cut points:
. a square root transformed difference  2.5 (the
difference beyond measurement error),
. an annualized percent change 15%.
he primary outcome was mortality verified from
he National Death Index. Cox proportional hazard
odeling was performed as implemented in SAS
oftware (version 9.2, SAS Institute, Cary, North
arolina). Covariates included in all models were
aseline CAC score, age, and sex. The length of
ime between the 2 scans was included as a covariate
n models other than those using annualized differ-
nce in progression of CAC. Hazard ratios (HR)
nd 95% confidence intervals (CI) are presented for
ontinuous variables, for 1 SD of continuous vari-
bles (standardized HR), and for the pre-defined put points. Standardized hazard ratios allow for
irect comparison of the effect size of the different
ontinuous exposure methods. Model comparisons
or different approaches for assessing progression of
AC scores within each study group used the
kaike information criterion for non-nested mod-
ls. A lower Akaike information criterion indicates
better fit to the data. We then tested the best
tting models by adding cardiovascular disease risk
actors (hypertension, diabetes, smoking, pre-
ature family history, and hypercholesterolemia) to
ssess for further adjustment of the hazard ratios.
To facilitate data interpretation and verification
f proportional hazards assumptions, CAC scores
ere classified into the following categories: 0, 1 to
0, 11 to 100, 101 to 400, and 400 (no identifi-
ble plaque, minimal plaque, mild plaque, moderate
laque, and extensive atherosclerotic plaque burden,
espectively) (13).
E S U L T S
he majority of patients (72.9%) were men, and the
ean age was 60.1  10.8 years. The mean
nterscan period (scan 1 to scan 2) was 3.1  2.0
ears (range 1 to 16 years). The prevalence of
ardiovascular risk factors was high: current tobacco
se: 6.2%; diabetes: 7.1%; high blood pressure:
3.6%, hypercholesterolemia: 41.2%; family history
f coronary artery disease: 40.4%. The CAC score
as a strong independent predictor of mortality
chi-square  51.02, p  0.0001). Mortality sig-
ificantly increased with increasing CAC score.
There were 288 deaths among the 4,609 individ-
als in the full cohort (Table 1). A priori analyses
ere planned for all patients (Table 1), patients
ith baseline CAC score 0 (n  2,866, 236
eaths) (Table 2), and those with baseline CAC
core 30 (n  2,183, 204 deaths) (Fig. 1).
For comparison purposes, subgroups were also
xamined: patients with baseline CAC  0, the
orollary of Table 2 (n  1,743, 52 deaths) (Table 3),
nd those with baseline CAC 30, the corollary of
able 3 (n  2,426, 84 deaths).
Progression of CAC was significantly associated
ith mortality regardless of the method used to
ssess progression (p  0.0001). Standardized HRs
anged from 1.12 (95% CI: 1.09 to 1.15) for
nnualized absolute CAC score increase, to 1.49
95% CI: 1.39 to 1.59) for the MESA method. The
est model to predict mortality, however, was the
QRT method (HR: 3.34, 95% CI: 2.65 to 4.21,
 0.0001), followed by the method that uses an
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1232nnualized increase in CAC score 15% in those
ith baseline CAC 30 (HR: 2.98, 95% CI: 2.20
o 4.95, p  0.0001), after controlling for baseline
AC, age, sex, and follow-up time between scans.
The effect of progression of CAC in individuals
ith CAC 0 at baseline is presented in Table 2.
here were 236 deaths among 2,866 individuals. As
n the full cohort, all methods for assessing progres-
ion of CAC were significantly related to mortality.
he best model was again based on the SQRT
ethod (HR: 3.66, 95% CI: 2.82 to 4.74, p 
.001).
The same concept held true in individuals with a
aseline CAC30 (n 2,183, 204 deaths), where,
hough all methods were predictive, the SQRT
ethod provided the best fit of the data with a
R  3.28 (95% CI: 2.48 to 4.32, p  0.001). In
econdary analyses, we examined the progression of
AC in individuals who had no detectable CAC at
he baseline visit (n  1,743, 52 deaths during
ollow-up) (Table 3). There was no significant
elationship between development of CAC and
ortality in these individuals.
Among individuals with baseline CAC score
30, progression of CAC was significantly associ-
ted with mortality. In this subgroup, the MESA
ethod provided the best fit of the data (HR: 2.85;
5% CI: 2.20 to 3.70; p  0.001).
Between Progression of Coronary Calcium and Mortality in the F
HR (95% CI) Standard
1.00 (1.00–1.00) 1.2
nce 2.5 3.34 (2.65–4.21)
nce 1.09 (1.07–1.10) 1.3
ifference 2.73 (2.32–3.22) 1.4
Cannot be calculated: % change  ∞ for base
Cannot be calculated: % change  ∞ for base
ct size for 1 unit change in the progression variable. Standardized HR represents th
del ﬁt. Models are adjusted for baseline coronary calcium, age, sex, and the leng
; Ln  natural log.
Between Progression of Coronary Calcium and Mortality in the I
hs)
HR (95% CI) Standardize
1.00 (1.00–1.00) 1.25 (1
nce 2.5 3.66 (2.82–4.74)
nce 1.08 (1.07–1.09) 1.42 (1
ifference 2.60 (2.19–3.09) 1.56 (1
1.00 (1.00–1.00) 1.08 (1
3.27 (2.43–4.41)
nit change in the progression variable. Standardized HR represents the effect size
oronary calcium, age, sex, and the length of time between the 2 scans.
1.Adjusting for cardiovascular disease risk factors
id not appreciably alter the relationship between
AC progression and mortality. Progression ad-
usted for baseline CAC, age, sex, and time between
cans yielded a HR  3.34 (95% CI: 2.65 to 4.21).
urther adjustment adding hypertension, hyper-
holesterolemia, diabetes, family history, and smok-
ng resulted in HR  3.32 (95% CI: 2.62 to 4.20,
 0.0001). Similarly, HR did not change signif-
cantly for models of prediction including baseline
AC 0 (HR:  3.62, 95% CI: 2.78 to 4.70, p 
.0001) or CAC 30 (HR: 3.22, 95% CI: 2.43 to
.27, p  0.0001).
We further examined the combined effect of the
resence of coronary calcium at baseline and pro-
ression of coronary calcium. Having CAC at
aseline and significant progression of CAC was a
ignificant predictor of future mortality (HR: 5.15,
5% CI: 3.67 to 7.22, p  0.0001) (Table 4).
djusting for cardiovascular disease risk factors did
ot appreciably alter the relationship between CAC
rogression and mortality (HR: 5.33, 95% CI: 3.74
o 7.60, p  0.0001). Having baseline CAC with-
ut significant progression was marginally associ-
ted with mortality (HR: 1.42, 95% CI: 0.99 to
.02, p  0.054). Those without CAC at baseline
ut with significant progression of CAC did not
ave an increase in the rate of mortality (p  0.97).
Cohort With No Exclusions (n  4,609, 288 Deaths)
d HR (95% CI) p Value AIC (Model Fit)
.17–1.25) 0.0001 4,424.570
0.0001 4,382.633
.30–1.43) 0.0001 4,388.108
.39–1.59) 0.0001 4,388.861
 0 with any change.
 0 with any change.
ct size for 1 SD of the progression variable. A lower Akaike information criterion
time between the 2 scans.
iduals With Baseline Coronary Calcium >0
(95% CI) p Value AIC (Model Fit)
1.29) 0.0001 3,426.888
0.0001 3,378.945
1.49) 0.0001 3,394.080
1.69) 0.0001 3,395.578
1.14) 0.0056 3,471.104
0.0001 3,407.634
SD of the progression variable. A lower AIC denotes a better model ﬁt. ModelsTable 1. Relationship ull
ize
Absolute difference 1 (1
 transformed differe
 transformed differe 6 (1
Ln transformed  25 d 9 (1
% change line
% change 15% line
Hazard ratio (HR) is the effe e effe
(AIC) denotes a better mo th ofTable 2. Relationship ndiv
(n  2,866, 236 Deat
d HR
Absolute difference .19–
 transformed differe
 transformed differe .34–
Ln transformed  25 d .44–
% change .02–
% change 15%
HR is the effect size for 1 u for 1
are adjusted for baseline c
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1233Progression in the setting of increasing baseline
AC using set cut points (1 to 10, 11 to 100, 101
o 400, and 400) was associated with increasing
isk of all-cause mortality (Fig. 2).
I S C U S S I O N
his is the first large study following patients for 1
o 16 years and submitted to repeat CT scans,
emonstrating incremental increase in mortality
ith progression of CAC over baseline score, time
etween scans, demographics, and cardiovascular
isk factors. The CAC score in itself, as shown in
ultiple studies before, is a strong independent
redictor of mortality. Because CAC can be located
nd quantified, changes over time can be analyzed
o that progression or regression can be determined.
t the moment, this is one of the few techniques
hat enables research to study this important ques-
ion, as outcome may be related more to the
ontinuous observation of changes over time than a
ingle determination once in a lifetime. The obser-
ation that progression of CAC is associated with
n adverse outcome extends prior reports linking
AC progression to coronary syndromes (1–3).
Prior smaller studies have suggested this effect.
aggi et al. (14) followed 269 asymptomatic sub-
ects for 2.5 years after being submitted to sequen-
ial CT scans; of the 22 cardiovascular disease
vents, 20 occurred in patients with progression of
AC and 2 among patients without progression
p  0.01). Another study of 225 subjects followed
or an average of 3 years after the repeat CT scan,
hose with new cardiac events had a significantly
reater annual change in CAC score than those
ho did not experience events (35% vs. 22%, p 
.04) (15). Moreover, 78% of patients with events
ad 20% annual progression versus 37% of those
ot experiencing events (p  0.001).
Among 817 asymptomatic subjects submitted to
equential CT scans approximately 2 years apart,
ean absolute and percent changes in CAC score
ere 147% and 47%, respectively, in those who
eveloped an MI after the second scan, compared
ith 63% and 26% in those without events (p 
.001 and p  0.01, respectively) (3). In another
BT study of 495 asymptomatic subjects receiving
tatins and submitted to more than 1 CT scan,
15% CAC progression was associated with a
7.2-fold (95% CI: 4.1 to 71.2) increased risk of MI
hen compared with patients without CAC pro-
ression (p  0.0001) (4). These relatively small wtudies suggested that continued accumulation of
AC in asymptomatic individuals is associated
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with coronary artery calcium  0, and (C) survival in participants w
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1234One large prospective study using CT to measure
rogression of CAC has also been reported. This
rospective observational study evaluated 4,613
symptomatic persons aged 50 to 70 years with
BT screening for CAC at baseline and again at 2
ears and the follow-up lasted 4.3 years (1). This
tudy demonstrated that the median (interquartile
ange) CAC scores increased by 4 (0, 38) units from
aseline to follow-up in subjects who did not
ustain a coronary event at any time during the
tudy. In contrast, median (interquartile range)
AC scores increased by 247 (40, 471) units in
ubjects who experienced a first coronary disease
vent after the follow-up scan (p  0.0001). Mul-
ivariable logistic regression analyses demonstrated
hat age (p  0.03), male sex (p  0.04), low-
ensity lipoprotein cholesterol (p  0.01), high-
ensity lipoprotein cholesterol (p  0.04), and
-year change in CAC score (p  0.0001) were
ignificantly associated with subsequent coronary
rtery disease events. The MESA (Multi-Ethnic
tudy of Atherosclerosis) (12) is following patients
fter a second CAC screen, and will assess subse-
uent cardiovascular events; however, results are
till 1 to 2 years away.
Between Progression of Coronary Calcium and Mortality in Indiv
HR (95% CI) Standard
0.99 (0.97–1.03) 0.9
nce 2.5 0.95 (0.43–2.10)
nce 0.93 (0.77–1.12) 0.8
ifference 0.82 (0.23–2.92) 0.9
Cannot be calculated: % change  ∞ for base
Cannot be calculated: % change  ∞ for base
nit change in the progression variable. Standardized HR represents the effect size
oronary calcium, age, sex, and the length of time between the 2 scans.
1.
Table 4. Relationship Between the Combined Effects of the
Presence of Baseline CAC With Signiﬁcant Progression of CAC
Compared With Those Without Either Baseline or Progression
of CAC and Mortality in the Full Cohort With No Exclusions
(n  4,609, 288 Deaths)
HR (95% CI) p Value
Baseline and progression 5.15 (3.67–7.22) 0.0001
Baseline only 1.42 (0.99–2.02) 0.055
Progression in CAC  0 0.94 (0.44–2.15) 0.97
Age 1.05 (1.04–1.06) 0.0001
Sex 1.38 (1.04–1.83) 0.03
Time between scans 0.95 (0.89–1.01) 0.13
Progression of coronary calcium was deﬁned as  transformed difference
2.5 based on the best ﬁtting model.
CAC  coronary artery calcium; other abbreviations as in Table 1.Baseline 0 scores were not predictive of progres-
ion or all-cause mortality in this study. This
urther validates the concept that a baseline 0 score
as a significant warranty period for both future
ardiovascular events and progression of atheroscle-
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Figure 2. Survival Curves Demonstrating Time to All-Cause
Mortality for Nonprogressors and Progressors
Cox proportional hazards survival curves demonstrating time to
all-cause mortality for patients with a yearly change using sur-
vival curve of progression based on our best ﬁtting model of
square root 2.5 according to baseline calcium score: (A) non-
progressors and (B) outcomes in progressors. CAC  coronary
als With Baseline Coronary Calcium  0 (n  1,743, 52 Deaths)
d HR (95% CI) p Value AIC (Model Fit)
.75–1.32) 0.9605 707.492
0.8914 707.476
.65–1.20) 0.4423 706.841
.72–1.27) 0.7595 707.396
 0 with any change.
 0 with any change.
SD of the progression variable. A lower AIC denotes a better model ﬁt. ModelsTable 3. Relationship idu
ize
Absolute difference 9 (0
 transformed differe
 transformed differe 9 (0
Ln transformed  25 d 6 (0
% change line
% change  15% line
HR is the effect size for 1 u for 1
are adjusted for baseline cartery calcium.
r
c
p
d
p
t
c
b
t
a
i
w
h
w
t
r
e
a
0
s
r
t
o
p
s
r
s
p
o
a
r
d
s
i
g

o
i
t
b
T
t
4
a

p
i
b
C
t
t
a
s
r
s
S
w
t
p
w
p
(
t
a
u
b
o
g
d
t
r
t
o
h
m
p
e
1
i
n
C
T
m
a
r
t
p
i
T
i
a
w
s
b
R
o
W
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 2 , 2 0 1 0
D E C E M B E R 2 0 1 0 : 1 2 2 9 – 3 6
Budoff et al.
CAC Progression Predicts All-Cause Mortality
1235osis (16,17). Min et al. (16) have suggested a 0
alcium score affords at least a 5-year warranty
eriod, and our study strongly supports that evi-
ence with even longer follow-up and interscan
eriods.
Our study provides strong confirmatory evidence
hat CAC progression is associated with future
ardiovascular events and, as radiation doses are
eing reduced to a minimum, that may be a useful
ool in the prevention armamentarium to assess
therosclerosis progression noninvasively. Measur-
ng CAC progression requires sequential CT scans,
ith a cumulative radiation exposure. Prior reports
ave raised concern about the excess risk of cancer
ith such an approach (18). However, such predic-
ions are outdated as current gating technology
educes the radiation dose substantially, with an
xpected dose of 1 mSv per scan (7). Further
dvances have reduced the CAC dose to as low as
.6 mSv, lower than screening mammography (19).
Strengths of this study include its large sample
ize and long follow-up. In addition, the scans were
ead in the same CT reading center that interprets
he MESA and multiple other National Institutes
f Health epidemiologic studies, with standardized
rotocols for acquisition and interpretation of CAC
cans (20).
Prior event studies of CAC progression have
eported on different techniques to assess progres-
ion. In this analysis, we compared previously re-
orted techniques to determine the best predictor of
utcomes with CAC progression. All methods for
ssessing progression of CAC were significantly
elated to mortality except in individuals with no
etectable CAC at baseline (score  0). Multiple
tudies have demonstrated the very low event rates
n persons without CAC (score  0) (17,21). In
eneral, a square root transformed difference of
2.5 provided the best fit of the data. This (20) and
ther methods (21) account for interscan variability
n CAC. This was true in the full cohort, among
hose with baseline CAC 0, and in those with a
aseline CAC 30, or 3 pre-defined subgroups.
he HRs for this cut point were 3.34 (95% CI: 2.65
o 4.21) in the full cohort, 3.66 (95% CI: 2.82 to
.74) in those with baseline coronary calcium 0,
nd 3.28 (95% CI: 2.48 to 4.32) in those with CAC
30. These analyses indicate that regardless of cut
oints, progression of CAC is related to a 3-fold
ncrease in mortality. The greatest risk was a com-
ination of moderate (100) or severe (400)
AC score and progression (Fig. 2). This supportshe hypothesis that whereas CAC represents life- mime accumulation of atherosclerosis and scarring
fter plaque rupture (22,23), progression demon-
trates the quiescence or activity of the atheroscle-
otic pathway and is an independent predictor of
urvival.
tudy limitations. The cardiovascular risk factors
ere taken by survey, rather than measured. None-
heless, the prevalence of hypercholesterolemia, hy-
ertension, and diabetes mellitus in our population
as similar to that observed in other large,
opulation-based studies of coronary heart disease
24). Additionally, the National Death Index ob-
ained for this study did not include cause of death
nd, as such, our models include mortality possibly
nrelated to atherosclerotic disease. However, the
ias resulting from death misclassification does not
ccur in all-cause mortality models and in this age
roup, the prevalence of coronary heart disease
eaths has been reported to be approximately one-
hird of death from all causes (25).
This is a single-center study, using the same CT
eading center as used in multiple National Insti-
utes of Health–sponsored studies. Reproducibility
f CAC scanning and scoring from this laboratory
as been previously reported (26,27). We used a
inimum interscan time of 10 months. Only 311
atients had follow-up 1 year. There is no differ-
nce if different time cut points are used. We used
0, 12, and 18 months as minimum without affect-
ng overall results, just lowering sample size (data
ot shown).
O N C L U S I O N S
he progression of CAC adds significant incre-
ental prediction ability of all-cause mortality, after
djustment for time between scans, demographics,
isk factors, and baseline CAC scores. It appears
hat persons with scores 30 can be assessed for
rogression of CAC, and this adds incremental
nformation regarding future prognostic risk.
hough use of repeat CT testing to estimate an
ndividual’s risk associated with CAC “change”
ppears to be of value, a better understanding of
hat therapies may be of benefit and how clinicians
hould use these data in clinical practice remains to
e determined.
eprints requests and correspondence: Dr. Matthew Bud-
ff, Los Angeles Biomedical Research Institute, 1124
est Carson Street, Torrance, California 90502. E-mail:
budoff@labiomed.org.
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